The Market Doesn't Like What It Sees From Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues Yet As Shares Tumble 30%
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. (NASDAQ:SGMO) share price has dived 30% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous t
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 price target.
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive Into Financials and Strategic Highlights
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the e
Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the expected value was -0.21 dollars.
Sangamo Therapeutics | 10-Q: Quarterly report
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results Showcased 20 presentations at the 27(th) American Society of Gene & Cell Therapy (ASGCT) Annual Meetin
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9,
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?